Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia - Heidel, F; Lipka, DB; von Auer, C (Thromb Haemost, 2007)